ClinicalTrials.gg
CompletedNCT07307794Updated Aug 27, 2026

To Evaluate the Adhesion of TK-254RX on Healthy Participants

A Phase 1 interventional study of Esflurbiprofen Topical System in Healthy Participants, sponsored by Teikoku Seiyaku Co., Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Teikoku Seiyaku Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study is a single-center, open-label, multiple-dose trial in healthy participants. The primary purpose of this study is to assess the adhesion of TK-254RX. Secondary purposes are to assess the safety of TK-254RX and the residual amount of the patch.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Teikoku Seiyaku Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age: 18 to 64 years
  • good state of health
  • written , after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the participants enrolled in the clinical trial

Exclusion criteria

Exclusion Criteria:

  • any injury of body which may induce the restriction of body movement
  • excessively hairy skin at application site
  • current or anamnestic known skin disorder (e.g., atopic dermatitis (eczema), neurodermatitis, contact allergy, psoriasis, vitiligo, melanoma, squamous cell carcinoma) or shaving hair at application site, which might interfere with the safety or tolerability of the active ingredient
  • history of excessive sweating/hyperhidrosis inclusive of application site
  • participation in a clinical study within 30 days before inclusion in the study or concomitantly
  • drug or alcohol abuse in the opinion of the investigator
  • pregnant and lactating women
  • women of (WOCBP) who do not agree to apply highly effective methods

    • Surgical sterilization
    • Hormonal contraception: combined (estrogen and progestogen containing) hormonal contraception, e.g., oral, intravaginal, transdermal, and progestogen-only hormonal contraception e.g. oral, injectable, implantable as well as intrauterine device (IUD) and intrauterine hormone-releasing system (IUS) each in combination with male condom to increase safety effect (double barrier method))
    • Bilateral tubal occlusion
    • Total abstinence throughout the study at the discretion of the Investigator
    • Periodic abstinence is not an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the study.
    • A woman who is and not surgically sterile must have a negative urine pregnancy test at screening but will not need to comply with an acceptable method of contraception. Women are considered post-menopausal and not of childbearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow up hormone level assessment.
  • known to Esflurbiprofen, R-flurbiprofen or one of the of the EFTS
  • existing cardiac and/or hematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • known liver or kidney insufficiency
  • existing gastrointestinal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  • history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
  • systolic blood pressure \< 90 or > 139 mmHg
  • diastolic blood pressure \< 60 or > 89 mmHg
  • pulse rate \< 50 bpm or > 90 bpm
  • assessment by investigator: "conspicuous"
  • participants who use any impermissible treatment or for whom restrictions apply
  • subject is vulnerable such as detained or committed to an institution by a court of law or by legal authorities or close affiliation with the sponsor or the site (e.g., a close relative of the investigator, dependent person (e.g., employee of or student at the investigational site), employee of the sponsor or affiliates)
  • subjects who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
  • subject with known bronchial asthma from previous history
  • Laboratory values are out of normal range
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    TK-254RX

    TK-254RX will be applied to the left or right lower leg above the ankle once daily over 3 consecutive days

    Drug: Esflurbiprofen Topical System

Interventions

  • DrugEsflurbiprofen Topical System

    The total of one TK-254RX per day for 3 days

06

What researchers measure

Primary outcomes

  1. Characterization of the patch adhesion

    Measuring the patch adhesion area by percentage visually by site staff, with the patch remaining adhered

    Time frame: Day 1 to Day 4

Secondary outcomes

  1. Recording adverse events and serious adverse events

    Characterization of the occurrence of adverse events or serious adverse events of TK-254RX

    Time frame: Day 1 to Day 4

  2. Residual amount of S-flurbiprofen

    Residual amount of S-flurbiprofen in the used patch applied on Day 3

    Time frame: Day 3 to Day 4

07

Study locations

1 site
  • Deutsche Sporthochschule Köln
    Am Sportpark Muengersdorf 6, Clogne 50933, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Mar 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartActual
Jan 19, 2026
Primary completionActual
Mar 3, 2026
CompletionActual
Mar 12, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07307794
Lead sponsor
Teikoku Seiyaku Co., Ltd.
Collaborators
SocraTec R&D GmbH, SocraMetrics GmbH, HWI pharma services GmbH, Clinsearch GmbH, CRM Biometrics GmbH
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Jan 19, 2026
Primary completion
Mar 3, 2026
Completion
Mar 12, 2026
Last update
Aug 27, 2026

Study contacts

Kenichi Nishiyama
study chair · Teikoku Seiyaku Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion